These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32627178)

  • 1. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse.
    Ledein L; Léger B; Dees C; Beyer C; Distler A; Vettori S; Boukaiba R; Bidouard JP; Schaefer M; Pernerstorfer J; Ruetten H; Jagerschmidt A; Janiak P; Distler JHW; Distler O; Illiano S
    Br J Pharmacol; 2020 Sep; 177(18):4296-4309. PubMed ID: 32627178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
    Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
    Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T; Yamamoto T
    Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.
    Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM
    Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis.
    Egal ESA; Kamdem SD; Yoshigi M; Yang CC; Pellizzari S; Kameni EM; Helms MN; Assassi S; Henkemeyer M; Frech TM; Mimche PN
    Arthritis Rheumatol; 2024 Aug; 76(8):1303-1316. PubMed ID: 38589317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor.
    Sakai N; Chun J; Duffield JS; Lagares D; Wada T; Luster AD; Tager AM
    Kidney Int; 2017 Mar; 91(3):628-641. PubMed ID: 27927603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA
    Olianas MC; Dedoni S; Onali P
    Eur J Pharmacol; 2020 Apr; 873():172963. PubMed ID: 32007501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
    Ong VH; Evans LA; Shiwen X; Fisher IB; Rajkumar V; Abraham DJ; Black CM; Denton CP
    Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
    Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
    Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
    Orvain C; Cauvet A; Prudent A; Guignabert C; Thuillet R; Ottaviani M; Tu L; Duhalde F; Nicco C; Batteux F; Avouac J; Wang N; Seaberg MA; Dillon SR; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):13. PubMed ID: 34986869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
    Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.
    Beyer C; Schramm A; Akhmetshina A; Dees C; Kireva T; Gelse K; Sonnylal S; de Crombrugghe B; Taketo MM; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):761-7. PubMed ID: 22328737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?
    Wei J; Melichian D; Komura K; Hinchcliff M; Lam AP; Lafyatis R; Gottardi CJ; MacDougald OA; Varga J
    Arthritis Rheum; 2011 Jun; 63(6):1707-17. PubMed ID: 21370225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antifibrotic Effect of A
    Karmouty-Quintana H; Molina JG; Philip K; Bellocchi C; Gudenkauf B; Wu M; Chen NY; Collum SD; Ko J; Agarwal SK; Assassi S; Zhong H; Blackburn MR; Weng T
    Arthritis Rheumatol; 2018 Oct; 70(10):1673-1684. PubMed ID: 29771006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.
    Laurent P; Allard B; Manicki P; Jolivel V; Levionnois E; Jeljeli M; Henrot P; Izotte J; Leleu D; Groppi A; Seneschal J; Constans J; Chizzolini C; Richez C; Duffau P; Lazaro E; Forcade E; Schaeverbeke T; Pradeu T; Batteux F; Blanco P; Contin-Bordes C; Truchetet ME
    Ann Rheum Dis; 2021 Dec; 80(12):1594-1603. PubMed ID: 34285051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
    Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M
    Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.